Trial · NCT06879379
KPD Consolidation After ASCT in NDMM Patients
NCT06879379, Phase 2, Phase 3, Recruiting, Peking University People's Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. KPD Consolidation After ASCT in NDMM Patients. Trials, record NCT06879379. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06879379
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- KPD Consolidation After ASCT in NDMM Patients
- NCT number
- NCT06879379
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 202 participants, estimated
- Lead sponsor
- Peking University People's Hospital
- Conditions
- Multiple Myeloma, Newly Diagnosed
- Interventions
- KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation
- First posted
- 2025-03-17
- Last updated
- 2025-03-17
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Minimal residual disease (MRD) negativity rate prior to maintenance therapy | 36 months | The primary endpoint of this study is to compare the minimal residual disease (MRD) negativity rate prior to maintenance therapy in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients who receive KPD consolidation therapy versus those who do not receive consolidation therapy after triplet or quadraplet induction therapy and autologous stem cell transplantation (ASCT). |
| Primary | Overall Response Rate (ORR) | 36 months | Compare the overall response rate (ORR) including the rates of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR), prior to maintenance therapy according to the IMWG (International Myeloma Working Group) assessment criteria, between the two treatment groups。 |
| Secondary | Progression-free survival (PFS) | 36 months | Time interval from ASCT to disease progression or death. |
| Secondary | Overall Survival (OS) | 36 months | Time interval from ASCT to death |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06879379
GET https://conductscience.org/api/trials/v1/NCT06879379/registered